- |||||||||| anastrozole / Generic mfg.
Effect of Anastrozole on Sperm Concentration in Male Patients with Idiopathic Infertility (Room 225) - Apr 10, 2022 - Abstract #AUA2022AUA_2291;
Conclusions : A subset of men with idiopathic infertility experience clinical improvement in semen parameters after initiating anastrozole therapy. Men with higher pre-treatment sperm concentrations and lower baseline FSH levels may be more likely to respond to treatment.
- |||||||||| anastrozole / Generic mfg.
U-shaped Association Between Secondary Hypogonadism and Body Mass Index: A Retrospective Analysis of Men with Testosterone Deficiency (Room 222) - Apr 10, 2022 - Abstract #AUA2022AUA_1806;
Men previously on testosterone replacement therapy (TRT), Clomiphene, or Anastrozole were excluded...For underweight men, this process may represent an adaptive response to an energy deficit, involving suppression of the hypothalamus due to dysregulation of ghrelin, leptin, and pro-inflammatory cytokines. These findings support screening for secondary hypogonadism in obese men to recommend weight loss and TRT to reduce cardiovascular related mortality, while increasing caloric intake in underweight men to improve libido and sexual function.
- |||||||||| anastrozole / Generic mfg.
Journal: Physical Activity and Its Association with Traditional Outcome Measures in Pulmonary Arterial Hypertension. (Pubmed Central) - Apr 6, 2022
Baseline data for 55 patients enrolled in PHANTOM (Pulmonary Hypertension and Anastrozole), an ongoing multicenter randomized controlled trial of anastrozole in PAH, were used...Increased daily activity was associated with greater six-minute walk distance and better HRQoL. Distinct activity-based phenotypes may be helpful in risk stratification of PAH patients or provide novel endpoints for clinical trials.
- |||||||||| Kisqali (ribociclib) / Novartis
Trial completion date, Trial primary completion date: Roll-over Study to Allow Continued Access to Ribociclib (clinicaltrials.gov) - Apr 6, 2022
P4, N=137, Not yet recruiting,
Recruiting --> Completed Trial completion date: Nov 2027 --> Feb 2028 | Trial primary completion date: Oct 2027 --> Jan 2028
- |||||||||| Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer (clinicaltrials.gov) - Apr 4, 2022
P3, N=1050, Active, not recruiting,
Longer follow-up is needed to assess any impact on breast cancer mortality. Recruiting --> Active, not recruiting | Trial completion date: Oct 2022 --> Jan 2023 | Trial primary completion date: Aug 2022 --> Jan 2023
- |||||||||| anastrozole / Generic mfg.
Journal, IO biomarker: Anastrozole regulates fatty acid synthase in breast cancer. (Pubmed Central) - Mar 31, 2022
Repressing FASN causes regression of breast cancer cell growth. The anastrozole-FASN signaling pathway is eminently targetable in endocrine-resistant breast cancer.
- |||||||||| Herceptin (trastuzumab) / Roche
Journal: Poorly Differentiated Scrotal Carcinoma With Apocrine Immunophenotype. (Pubmed Central) - Mar 23, 2022
Molecular analysis (n = 2) detected a HER-2 mutation in one and microsatellite instability in another. Although the presence of an intraepidermal pagetoid component could hint toward the diagnosis of invasive extramammary Paget disease, tumors without an intraepidermal component could be diagnostically challenging given the lack of morphologic evidence of apocrine differentiation.
- |||||||||| Orserdu (elacestrant) / Menarini
Trial primary completion date, Monotherapy, Metastases: EMERALD: Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (clinicaltrials.gov) - Mar 21, 2022
P3, N=466, Active, not recruiting,
Although the presence of an intraepidermal pagetoid component could hint toward the diagnosis of invasive extramammary Paget disease, tumors without an intraepidermal component could be diagnostically challenging given the lack of morphologic evidence of apocrine differentiation. Trial primary completion date: Aug 2021 --> Aug 2022
- |||||||||| NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date, Metastases: POLLY: ER Reactivation Therapy for Breast Cancer (clinicaltrials.gov) - Mar 17, 2022
P2, N=19, Active, not recruiting,
Although limited by the small sample size, these results are reassuring that the combination of abemaciclib plus anastrazole appears to be active in the early setting regardless of baseline BMI. Trial completion date: Apr 2022 --> Sep 2022 | Trial primary completion date: Jan 2022 --> Jun 2022
- |||||||||| Ibrance (palbociclib) / Pfizer
Tumor microenvironment heterogeneity identifies potential biomarkers of response in ER-positive breast cancers treated with palbociclib (E-Poster Website) - Mar 9, 2022 - Abstract #AACR2022AACR_7706;
Transcriptomic analysis showed that while CXCL1, CCL17, CCL13, CXCL9, and CCL5 expression correlated with the high density of CD4 and CD8 T cells in the stromal component cluster, VEGFA, IL1B, CXCL16, CCL3, and CCL7 were increased in the CD163+ and CD68+ macrophage-enriched clusters, indicating that differential cytokine expression is associated with the tumor architecture.Comprehensively characterizing, via MxIF, the immune microenvironment of ER+ HER2- breast cancer provided resolution of cellular architecture and elucidated spatial relationships among the immune and stromal cells of the tumor. Quantitatively assessing breast tumor cell-to-cell interactions has the potential to identify imaging markers of response, ultimately leading to the development of effective therapy options.
- |||||||||| anastrozole / Generic mfg.
Increased androgen secreted levels promote anti-proliferative effects on triple negative breast cancer (E-Poster Website) - Mar 9, 2022 - Abstract #AACR2022AACR_6748;
To this purpose, we evaluated the efficacy of Dutasteride (a 5α-Reductase inhibitor) and Anastrozole (an aromatase inhibitor) in three TNBC cell lines, SUM-149, SUM-159 and MDA-MD-231; and another no TNBC cell line, MCF-7...In conclusion, dutasteride and anstrozole promote a reduction in cell proliferation by increasing the secreted levels of androgens. The combination of these treatments with potent inhibitors of estrogen secretion may result in a promising treatment for TNBC.
- |||||||||| anastrozole / Generic mfg., fulvestrant / Generic mfg.
The effect of intrinsic subtype on inhibition of tumor growth by anastrozole vs. fulvestrant vs. the combination: Results from the Alliance neoadjuvant endocrine therapy (NET) ALTERNATE trial. (Great Hall BC, Convention Center) - Mar 9, 2022 - Abstract #AACR2022AACR_1715;
P3
This suggests that A+F may be a more effective adjuvant endocrine therapy than A alone in LumB disease. The lower Ki67 suppression with A alone also suggests that poorer outcome in some LumB tumors may be due to insufficient ER targeting rather than ER-independent tumor growthSupport: U10CA180821, U10CA180882, U24CA196171, UG1CA189856, U10CA180868 (NRG), NCI BIQSFP, BCRF, Genentech, AstraZeneca.
- |||||||||| letrozole / Generic mfg., anastrozole / Generic mfg.
Evaluation of the Behavior of the Dispensing of Drugs for Breast Cancer in a Cohort of Patients in Colombia (In-person & Virtual) - Mar 8, 2022 - Abstract #ISPOR2022ISPOR_448;
The total cohort had 3,076 patients dispensed since January 1, 2020, 22.5% of the patients had up to 4 treatments delivered in the analysis period, the treatment with the highest dispensation was Anastrozole in 29.5%, followed by Letrozole 23.3% used in initial lines of treatment. A trend is observed in the use of low-cost medications in the analysis cohort that is maintained during follow-up, however, the cost differential in the lines of treatment analyzed is high, therefore, timely treatment would generate savings associated with use of first-line treatments.
- |||||||||| Ibrance (palbociclib) / Pfizer
Trial completion date, Trial primary completion date, Metastases: Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer (clinicaltrials.gov) - Mar 8, 2022
P2, N=40, Recruiting,
Further analysis is necessary to better understand management decisions for this group of patients cared for within CHS. Trial completion date: Oct 2022 --> Jun 2026 | Trial primary completion date: Jan 2022 --> Jun 2026
- |||||||||| Kisqali (ribociclib) / Novartis
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: AMICA: Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer (clinicaltrials.gov) - Mar 8, 2022
P2, N=150, Active, not recruiting,
Trial completion date: Oct 2022 --> Jun 2026 | Trial primary completion date: Jan 2022 --> Jun 2026 Recruiting --> Active, not recruiting | Trial completion date: Mar 2022 --> Jul 2022 | Trial primary completion date: Mar 2022 --> Jul 2022
- |||||||||| letrozole / Generic mfg., anastrozole / Generic mfg.
Clinical, Journal: Clinical application of aromatase inhibitors to treat male infertility. (Pubmed Central) - Mar 3, 2022
This narrative review has summarized the target patients, dose, treatment duration and side-effects of AIs. Polymorphisms of CYP19A1 that may affect AIs treatment efficacy were also summarized, but a full understanding of the mechanisms involved in AIs action requires further study.
- |||||||||| Verzenio (abemaciclib) / Eli Lilly
P1 data, Journal, Combination therapy: Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study. (Pubmed Central) - Mar 1, 2022
P1b
Abemaciclib is a selective inhibitor of CDK4 and CDK6 approved for administration on a continuous dosing schedule as monotherapy or as combination therapy with an aromatase inhibitor or fulvestrant in patients with advanced or metastatic breast cancer...Sixty-seven patients were enrolled and received abemaciclib 200 mg every 12 hours in combination with letrozole (Part A, n=20), anastrozole (Part B, n=16), tamoxifen (Part C, n=16), or exemestane (Part D, n=15)...Abemaciclib in combination with multiple endocrine therapy options exhibited manageable safety and promising antitumor activity in patients with HR+, HER2- MBC. https://clinicaltrials.gov/, identifier NCT02057133.
- |||||||||| Herceptin (trastuzumab) / Roche
Clinical, Journal: Ovarian tissue cryopreservation in a patient with breast cancer during pregnancy: a case report. (Pubmed Central) - Feb 26, 2022
OTC for fertility preservation in patients with PrBC does not delay breast surgery, radiotherapy or chemotherapy, which is essential for effective treatment of breast cancer. We assess this method as a promising fertility preservation method which was used here for the first time worldwide in a patient who developed breast cancer during pregnancy.
- |||||||||| Kisqali (ribociclib) / Novartis
A Case Report of Ribociclib-Induced Pneumonitis (Area F, Hall F (North Building, Exhibition Level), Moscone Center) - Feb 19, 2022 - Abstract #ATS2022ATS_991;
Ribociclib was discontinued and the patient improved symptomatically with return to baseline level of function.Reports of CDK 4/6 inhibitor drug-associated lung injury are limited There has been only one case report outside of clinical trials of Ribociclib pneumonitis.7 As these drugs become more commonly used, it is important for clinicians to be aware of this potentially fatal drug associated lung injury. Treatment with drug cessation has varying responses from recovery like in our patient to death.
- |||||||||| letrozole / Generic mfg., anastrozole / Generic mfg.
Review, Journal: Should Skeletal Maturation Be Manipulated for Extra Height Gain? (Pubmed Central) - Feb 12, 2022
Administration of letrozole to boys with constitutional delay of growth puberty may increase AH, and rhGH plus anastrozole may increase AH in boys with growth hormone deficiency or idiopathic short stature, but the lack of data on attained AH and potential selective loss-of-follow-up in several studies precludes firm conclusions. GnRHas appear to have a good overall safety profile, while for aromatase inhibitors conflicting data have been reported.
- |||||||||| Eligard (leuprolide acetate) / Tolmar, Sanofi
Trial completion date, Trial primary completion date, Combination therapy: OVELIA: Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer (clinicaltrials.gov) - Feb 10, 2022
P3, N=250, Recruiting,
Trial completion date: Dec 2022 --> Jul 2023 | Trial primary completion date: Apr 2020 --> Jul 2022 Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
- |||||||||| tamoxifen / Generic mfg.
Retrospective data, Journal, Real-world evidence: Lipid Changes During Endocrine Therapy in Breast Cancer Patients: The Results of a 5-Year Real-World Retrospective Analysis. (Pubmed Central) - Feb 4, 2022
For premenopausal BC patients, LDL levels rapidly decreased at 1 year in the tamoxifen (TAM) group compared with baseline levels (p<0.05), and this decline remained for the following 4 years...For postmenopausal BC patients, there was no significant difference in the lipid profiles (TG, TC, LDL and HDL) in the letrozole (LET), anastrozole (ANA) or exemestane (EXE) groups compared with the nonendocrine group...TAM may improve LDL and TC levels in premenopausal BC patients. In postmenopausal BC patients, aromatase inhibitors (AIs) may have no adverse effects on lipid profiles, and TAM may have limited beneficial effects on serum lipids.
- |||||||||| letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Trial completion date, Trial primary completion date: Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (clinicaltrials.gov) - Feb 4, 2022
P3, N=10000, Active, not recruiting,
In postmenopausal BC patients, aromatase inhibitors (AIs) may have no adverse effects on lipid profiles, and TAM may have limited beneficial effects on serum lipids. Trial completion date: Feb 2022 --> Feb 2023 | Trial primary completion date: Feb 2022 --> Feb 2023
- |||||||||| tamoxifen / Generic mfg.
AROMATASE INHIBITORS - CANCER KILLERS OR HEART KILLERS? (eAbstract site) - Jan 28, 2022 - Abstract #ACC2022ACC_6512;
These CV events may explain why AI improves cancer-free survival, but not overall survival. This is the first potential case report of ACS as an early cardiotoxic manifestation of AI.
|
